CBT 102A
Alternative Names: CBT102-ALatest Information Update: 21 Sep 2023
At a glance
- Originator Hedu Biotechnology (Shanghai)
- Class Bacteria; Gene therapies; Probiotics
- Mechanism of Action Bacteria replacements; Gastrointestinal microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Clinical Phase Unknown Phenylketonuria
Most Recent Events
- 02 Sep 2023 Clinical trials in Phenylketonuria (In children, In adolescents) in China (PO) (NCT05948020)
- 25 Jul 2023 Hedu Biotechnology (Shanghai) plans clinical trial for Phenylketonuria (In children, In adolescents) (PO) (NCT05948020)
- 25 Jul 2023 CBT 102A is available for licensing as of 25 Jul 2023. http://www.commbiotx.com/EN/View.aspx?cid=2627 (CommBio Therapeutics website, July 2023)